The FDA granted conditional approval to Epizyme's Tazverik, or tazemetostat, to treat patients with inoperable metastatic or locally advanced epithelioid sarcoma, a rare soft tissue cancer, and Epizyme announced the drug will be priced at $15,500 per month. Data from a midstage trial showed the drug shrank tumors in some patients.
Epizyme's Tazverik gains conditional approval for rare soft tissue sarcoma
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.